Navigation Links
EntreMed Reports Second Quarter 2008 Financial Results
Date:8/6/2008

EntreMed to Conduct Update Call on Tuesday, August 12, 2008

ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial results for the three and six-month periods ending June 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

The Company reported a net loss for the second quarter of 2008 of ($9.6 million), or ($0.11) per share. This compares with a net loss of ($7.9 million), or ($0.10) per share, for the same period last year. For the first six months of 2008 the reported net loss was ($17.9 million), or ($0.22) per share as compared to ($15.6 million), or ($0.19) per share for 2007. The 2008 net loss for the three and six-month periods include a non-cash charge of $2.0 million, which represents a purchase price adjustment milestone triggered by the dosing of the first patient in a clinical trial for ENMD-2076, the lead molecule in our Aurora kinase program acquired from Miikana Therapeutics in January 2006.

The Company did not report any revenues for the first six months of 2008, although the Company believes that it will record royalty revenues in excess of $7 million on sales of Thalomid(R) by Celgene in the third and fourth quarters of 2008. As of June 30, 2008, EntreMed had cash and short-term investments of approximately $36 million.

Dane Saglio, EntreMed Chief Financial Officer, commented on the second quarter results, "During the second quarter of 2008, we recorded a $2.0 million non-cash charge resulting from the Company's dec
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
2. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
3. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
4. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
5. EntreMed Receives Nasdaq Deficiency Notice
6. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
7. EntreMed Announces 2008 Corporate and Clinical Program Priorities
8. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
9. EntreMed to Present at BIO CEO and Investor Conference
10. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
11. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... - 2014 Summary Global Markets Direct,s, ... - 2014, provides an overview of the Pacific ... This report provides comprehensive information on the ... LLC,s, complete with comparative analysis at various stages, ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... September 30, 2014 Shimadzu Scientific ... an easy-to-use and highly precise tool for measuring ... considerable elongation. With 1000-mm maximum movement distance, the ... for a gauge length of 10 mm. In ... accuracy above 50-mm stroke and within +/- 100 ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... to kill nematodes. Nematodes are microscopic parasitic roundworms, ... water, and inside other plants and animals. Nematicides ... volatility or other properties promoting migration through the ... more than 1,000 plant-parasitic nematodes. With more than ...
Breaking Biology Technology:Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2
... ... as the sample collection kit for MyCeliacID™ a saliva-based genetic test dedicated to celiac ... sample collection challenges inherent with traditional collection methods which are often too costly and ... Ottawa, ...
... , CANTON, Mass., Aug. 18 ... than 500 pieces of state-of-the-art R&D equipment that is no ... EquipNet as the exclusive seller and listed the premium lab ... online venue for pre-owned equipment. , , ...
... , , , , ... Inc., (NYSE: CRY ) an implantable biological medical device ... of the CryoPatch((R)) SG pulmonary human cardiac patch since FDA clearance. ... of Michigan C.S. Mott Children,s Hospital in Ann Arbor, MI by ...
Cached Biology Technology:DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 2DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test 3Massive Inventory of Premium Lab & Analytical Equipment Now Available 2CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material 2CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material 3CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material 4
(Date:9/30/2014)... news release is available in German . ... in their behavioural response to risky situations such as ... for Ornithology now found in a long-term study on ... with both metabolic rate and ambient temperature. High metabolic ... behaviour, as in these scenarios birds were more likely ...
(Date:9/30/2014)... Ill. (September 30, 2014) People who suffer from ... do to control their asthma besides properly taking medications ... new article in the Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), asthma sufferers ... their lifestyle. The woman described in the Annals article ...
(Date:9/29/2014)... confirms that the exposure to tar tended to be ... cigarettes. Similarly, exposure to nicotine tended to be ... of cigarette in several countries around the world. Previous ... chemicals in the smoke of these cigarettes are lower ... of chemicals in the smoke are not necessarily linked ...
Breaking Biology News(10 mins):Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2Slim cigarette smokers not exposed to more harmful chemicals 2
... FL. If you think you eat healthier at the Sunburst ... be wrong. You could be a victim of the "Health ... Consumer Research conference in Jacksonville, FL, showed that people eating ... 56% as many calories as they actually did. The ...
... direct evidence that taking up smoking results in epigenetic changes ... reported at the 35th Congress of the European Society for ... smoking and cancer has been established for decades, explained Dr ... Cancer Studies, Birmingham, who presented the results. Smoking is the ...
... lung cancer patients seem to live longer and experience delays ... cancer-associated molecule called MET is added to treatment with erlotinib, ... Dr David Spigel, Director of lung cancer research for the ... findings at the 35th Congress of the European Society for ...
Cached Biology News:Study reveals cancer-linked epigenetic effects of smoking 2New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer 2
Component of HyperMu™ Insertion Kit...
Request Info...
... , Maintenance 112 days/each ... Immunizations/Boost injections x5 /each , ... , Production bleed (25 ml blood =12 ... 100 ml blood (~50 ml serum) x1 each , ...
... g protein in 200 l SDS-PAGE Western blotting ... Abelson transformed macrophage cells, whole ... should be stored at -20C ... sample vial should be boiled ...
Biology Products: